A Phase 3 interventional study of Brexpiprazole and Placebo in Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 49 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 4th largest by enrollment, is the only one that started in 2012, is one of 16 in phase 3, and was the 12th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 524 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 13th largest by enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2012, is one of 50 in phase 3, and was the 50th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo comparator for 52 weeks
Drug: Placebo
Brexpiprazole (OPC-34712) for 52 weeks
Drug: Brexpiprazole
Brexpiprazole tablets 1 to 4 mg /day
Placebo comparator for 52 weeks
Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C.
The primary efficacy variable was time to impending relapse from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \>4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content).OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.The measure type, number is Hazard Ratio.
Time frame: From randomization to time of exacerbation of psychotic symptoms/impending relapse - up to 52 weeks
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase
Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual though content) to a score of \>4 and an absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Current suicidal behavior as assessed by the C-SSRS (ie, an answer of "yes" to any of the questions on the suicidal behavior section of the C-SSRS 5) Violent or aggressive behavior resulting in clinically significant self-injury to another person, or property damage.
Time frame: Baseline and Week 52/Early Termination
Percentage of Participants Meeting Stability Criteria in Double Blind Maintenance Phase
Participants were assessed for stability using the following criteria:1) Outpatient status AND 2) Positive and Negative Syndrome Scale (PANSS) Total Score ≤ 70 AND 3) A score of ≤ 4 (moderate) on each of the following PANSS items (possible scores of 1 to 7 for each item): conceptual disorganization, suspiciousness hallucinatory behavior, unusual thought content, AND 4) Clinical Global Impression - Severity of Illness scale(CGI-S) score ≤ 4 (moderately ill) AND 5) No current suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), defined as the following: An answer of "no" to each question on the Suicidal Behavior section of the C-SSRS AND an answer of "no" to Questions 4 and 5 on the Suicidal Ideation section of the C-SSRS, if completed, AND 6) No evidence of aggressive or violent behavior resulting in clinically significant self-injury, injury to another person, property damage.
Time frame: Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score - MMRM Analysis
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Total Score - Last-observation-carried-forward (LOCF) Analysis
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Positive Subscale Score - MMRM Analysis
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Positive Subscale Score - LOCF Analysis
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Negative Subscale Score - MMRM Analysis
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Negative Subscale Score - LOCF Analysis
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint - MMRM Analysis
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline, Weeks 6, 12, 24, 36 and 52
Change From Baseline in CGI-S Score at Endpoint - LOCF Analysis
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Clinical Global Impression - Improvement Score (CGI-I) at Endpoint - LOCF Analysis
The rater or investigator would rate the participant's total improvement whether or not it is due entirely to study treatment. During Phase B, responses were compared to the participant's condition at Baseline of Phase B (for participants who entered Phase B directly after screening) or to the End of Phase A visit (for participants who participated in Phase A). During Phase C, responses were compared to the participant's condition at the End of Phase B visit. Response choices include: 0 = Not assessed, 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse.
Time frame: Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in Personal and Social Performance (PSP) Scale Score - MMRM Analysis
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.
Time frame: Baseline and Weeks 24 and 52
Mean Change From Baseline in PSP Scale Score - LOCF Analysis
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.
Time frame: Baseline and Weeks 24 and 52
Mean Change From Baseline in Global Assessment of Functioning (GAF) Scale Score - MMRM Analysis
The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.
Time frame: Baseline and Weeks 12, 24, 36 and 52
Mean Change From Baseline in GAF Scale Score - LOCF Analysis
The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.
Time frame: Baseline and Weeks 12, 24, 36 and 52
Percentage of Participants Who Discontinued Due to All Causes
Analysis of the percentage of participants who discontinued due to all causes was based on all participants who have been randomized and taken one dose of IMP in the Double-blind Maintenance phase. The trial was completed by sponsor when efficacy was demonstrated at the first pre-specified interim analysis (45 impending relapse events) performed by an independent (unblinded) statistician.
Time frame: Baseline to Week 52
Mean Change From Baseline in PANSS Excited Component (PEC) Score - MMRM Analysis
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PEC Score - LOCF Analysis
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - MMRM Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Positive Symptoms Score - LOCF Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - MMRM Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Negative Symptoms Score - LOCF Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - MMRM Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Disorganized Thought Score - LOCF Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - MMRM Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Uncontrolled Hostility/Excitement Score - LOCF Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - MMRM Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
Mean Change From Baseline in PANSS Marder Factor Scores: Anxiety/Depression Score - LOCF Analysis
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline and Weeks 6, 12, 24, 36 and 52
A total of 753 participants were screened at 49 trial sites in the following 7 countries: United States (US, including Puerto Rico), Malaysia, Colombia, Romania, Ukraine, Serbia, and Turkey.
| Milestone | Phase A (Conversion Phase) | Phase B (Stabilization Phase) | Phase C - Brexpiprazole (Double-Blind Maintenance Phase) | Phase C - Placebo (Double-Blind Maintenance Phase) |
|---|---|---|---|---|
| Started | 406 | 0 | 0 | 0 |
| Completed | 346 | 0 | 0 | 0 |
| Not completed | 60 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 3 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 16 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event without impending relapse | 8 | 0 | 0 | 0 |
| Withdrew: Terminated study on interim analysis | 19 | 0 | 0 | 0 |
| Milestone | Phase A (Conversion Phase) | Phase B (Stabilization Phase) | Phase C - Brexpiprazole (Double-Blind Maintenance Phase) | Phase C - Placebo (Double-Blind Maintenance Phase) |
|---|---|---|---|---|
| Started | 0 | 464 | 0 | 0 |
| Completed | 0 | 202 | 0 | 0 |
| Not completed | 0 | 262 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 16 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 22 | 0 | 0 |
| Withdrew: Physician decision | 0 | 11 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 60 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 21 | 0 | 0 |
| Withdrew: Adverse event without impending relapse | 0 | 43 | 0 | 0 |
| Withdrew: Terminated study on interim analysis | 0 | 86 | 0 | 0 |
| Milestone | Phase A (Conversion Phase) | Phase B (Stabilization Phase) | Phase C - Brexpiprazole (Double-Blind Maintenance Phase) | Phase C - Placebo (Double-Blind Maintenance Phase) |
|---|---|---|---|---|
| Started | 0 | 0 | 97 | 105 |
| Completed | 0 | 0 | 14 | 9 |
| Not completed | 0 | 0 | 83 | 96 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 6 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 3 | 3 |
| Withdrew: Physician decision | 0 | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 10 |
| Withdrew: Lack of efficacy without ae | 0 | 0 | 11 | 30 |
| Withdrew: Adverse event without impending relapse | 0 | 0 | 4 | 2 |
| Withdrew: Terminated study on interim analysis | 0 | 0 | 49 | 38 |
The primary efficacy variable was time to impending relapse from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \>4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content).OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.The measure type, number is Hazard Ratio.
| Days | Brexpiprazole | Placebo |
|---|---|---|
| Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C. | 0.292 (0.156 to 0.548) | 3.420 (1.825 to 6.411) |
Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or an increase on any of the following individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual though content) to a score of \>4 and an absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Current suicidal behavior as assessed by the C-SSRS (ie, an answer of "yes" to any of the questions on the suicidal behavior section of the C-SSRS 5) Violent or aggressive behavior resulting in clinically significant self-injury to another person, or property damage.
| percentage of participants | Brexpiprazole | Placebo |
|---|---|---|
| Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria in the Double-blind Maintenance Phase | 13.54 | 38.46 |
Participants were assessed for stability using the following criteria:1) Outpatient status AND 2) Positive and Negative Syndrome Scale (PANSS) Total Score ≤ 70 AND 3) A score of ≤ 4 (moderate) on each of the following PANSS items (possible scores of 1 to 7 for each item): conceptual disorganization, suspiciousness hallucinatory behavior, unusual thought content, AND 4) Clinical Global Impression - Severity of Illness scale(CGI-S) score ≤ 4 (moderately ill) AND 5) No current suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), defined as the following: An answer of "no" to each question on the Suicidal Behavior section of the C-SSRS AND an answer of "no" to Questions 4 and 5 on the Suicidal Ideation section of the C-SSRS, if completed, AND 6) No evidence of aggressive or violent behavior resulting in clinically significant self-injury, injury to another person, property damage.
| percentage of participants | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 92.59 | 86.90 |
| Week 12 (N= 73, 68) | 93.15 | 86.76 |
| Week 24 (N= 50, 36) | 96.00 | 94.44 |
| Week 36 (N= 33, 24) | 93.94 | 83.33 |
| Week 52 (N= 15, 9) | 86.67 | 88.89 |
| Last Visit (N= 96, 104) | 79.17 | 56.73 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.79 ± 1.31 | 4.09 ± 1.27 |
| Week 12 (N= 73, 68) | 0.84 ± 1.73 | 6.15 ± 1.74 |
| Week 24 (N= 50, 36) | -1.88 ± 1.39 | 2.89 ± 1.55 |
| Week 36 (N= 33, 24) | -2.71 ± 1.48 | 3.33 ± 1.70 |
| Week 52 (N= 15, 9) | 0.61 ± 3.34 | 6.92 ± 4.53 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.51 ± 1.40 | 3.56 ± 1.28 |
| Week 12 | 1.55 ± 1.77 | 6.60 ± 1.62 |
| Week 24 | 1.58 ± 1.88 | 9.17 ± 1.72 |
| Week 36 | 2.49 ± 1.89 | 10.51 ± 1.73 |
| Week 52 | 3.25 ± 1.94 | 11.20 ± 1.77 |
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.17 ± 0.42 | 1.28 ± 0.41 |
| Week 12 (N= 73, 68) | -0.06 ± 0.50 | 1.81 ± 0.51 |
| Week 24 (N= 50, 36) | -0.84 ± 0.46 | 0.72 ± 0.51 |
| Week 36 (N= 33, 24) | -0.97 ± 0.44 | 0.91 ± 0.51 |
| Week 52 (N= 15, 9) | -1.21 ± 0.73 | 1.50 ± 0.99 |
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.30 ± 0.49 | 1.25 ± 0.45 |
| Week 12 | 0.38 ± 0.59 | 2.24 ± 0.54 |
| Week 24 | 0.49 ± 0.64 | 3.23 ± 0.59 |
| Week 36 | 0.97 ± 0.63 | 3.91 ± 0.58 |
| Week 52 | 0.99 ± 0.64 | 4.17 ± 0.59 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | -0.04 ± 0.37 | 0.65 ± 0.35 |
| Week 12 (N= 73, 68) | -0.22 ± 0.43 | 0.55 ± 0.44 |
| Week 24 (N= 50, 36) | -0.78 ± 0.39 | 0.18 ± 0.42 |
| Week 36 (N= 33, 24) | -1.03 ± 0.47 | 0.02 ± 0.53 |
| Week 52 (N= 15, 9) | 1.30 ± 1.37 | 0.87 ± 1.71 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | -0.12 ± 0.39 | 0.63 ± 0.35 |
| Week 12 | -0.17 ± 0.46 | 1.06 ± 0.42 |
| Week 24 | -0.08 ± 0.49 | 1.47 ± 0.44 |
| Week 36 | -0.14 ± 0.51 | 1.44 ± 0.46 |
| Week 52 | 0.39 ± 0.54 | 1.63 ± 0.49 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | -0.01 ± 0.09 | 0.26 ± 0.09 |
| Week 12 (N= 73, 68) | -0.01 ± 0.11 | 0.37 ± 0.11 |
| Week 24 (N= 50, 36) | -0.16 ± 0.10 | 0.21 ± 0.10 |
| Week 36 (N= 33, 24) | -0.31 ± 0.11 | 0.25 ± 0.12 |
| Week 52 (N= 15, 9) | -0.23 ± 0.17 | 0.28 ± 0.22 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | -0.08 ± 0.09 | 0.17 ± 0.09 |
| Week 12 | -0.04 ± 0.11 | 0.32 ± 0.10 |
| Week 24 | -0.03 ± 0.11 | 0.47 ± 0.10 |
| Week 36 | -0.00 ± 0.11 | 0.56 ± 0.10 |
| Week 52 | 0.02 ± 0.11 | 0.55 ± 0.11 |
The rater or investigator would rate the participant's total improvement whether or not it is due entirely to study treatment. During Phase B, responses were compared to the participant's condition at Baseline of Phase B (for participants who entered Phase B directly after screening) or to the End of Phase A visit (for participants who participated in Phase A). During Phase C, responses were compared to the participant's condition at the End of Phase B visit. Response choices include: 0 = Not assessed, 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 3.68 ± 0.98 | 4.00 ± 1.14 |
| Week 12 | 3.66 ± 1.19 | 4.10 ± 1.30 |
| Week 24 | 3.67 ± 1.27 | 4.30 ± 1.32 |
| Week 36 | 3.71 ± 1.27 | 4.39 ± 1.30 |
| Week 52 | 3.77 ± 1.26 | 4.40 ± 1.32 |
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 24 (N= 50, 36) | 18.85 ± 1.51 | 17.84 ± 1.82 |
| Week 52 (N= 15, 9) | 18.63 ± 2.76 | 12.55 ± 3.48 |
The PSP is a validated clinician-rated scale that measures personal and social functioning in four domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains is rated as absent, mild, manifest, marked, severe, or very severe. These ratings are then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 are considered to have mild functional difficulty. Scores of 31 to 70 represent manifest disabilities of various degrees and ratings of 1 to 30 indicate minimal functioning that requires intense support and/or supervision.The PSP score ranges from 0 to 100, with higher scores indicating higher levels of social functioning.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 24 | 15.20 ± 1.41 | 11.41 ± 1.32 |
| Week 52 | 15.06 ± 1.43 | 10.31 ± 1.34 |
The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 12 (N= 73, 68) | 1.59 ± 1.27 | -0.03 ± 1.29 |
| Week 24 (N= 50, 36) | 3.74 ± 1.42 | 1.09 ± 1.57 |
| Week 36 (N= 33, 24) | 4.71 ± 1.50 | 0.21 ± 1.67 |
| Week 52 (N= 15, 9) | 5.72 ± 1.87 | -0.16 ± 2.37 |
The GAF is a clinician-rated scale that assesses the participant's psychological, social, and occupational functioning on a hypothetical continuum of mental health-illness using a scale that ranges from 1 to 100 score, where lower values indicate worst outcome. From among 10 descriptive anchors, investigators will choose the anchor which is the most representative of the participant's level of functioning at the time of the assessment and will assign a single score within the point range given for the selected anchor.
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 12 | 0.44 ± 1.26 | -3.44 ± 1.17 |
| Week 24 | 0.85 ± 1.37 | -4.51 ± 1.27 |
| Week 36 | 0.97 ± 1.35 | -5.84 ± 1.25 |
| Week 52 | 0.55 ± 1.38 | -6.01 ± 1.28 |
Analysis of the percentage of participants who discontinued due to all causes was based on all participants who have been randomized and taken one dose of IMP in the Double-blind Maintenance phase. The trial was completed by sponsor when efficacy was demonstrated at the first pre-specified interim analysis (45 impending relapse events) performed by an independent (unblinded) statistician.
| Percentage of particpants | Brexpiprazole | Placebo |
|---|---|---|
| Percentage of Participants Who Discontinued Due to All Causes | 34.38 | 54.81 |
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.32 ± 0.23 | 0.74 ± 0.22 |
| Week 12 (N= 73, 68) | 0.50 ± 0.34 | 1.16 ± 0.35 |
| Week 24 (N= 50, 36) | -0.06 ± 0.31 | 0.45 ± 0.36 |
| Week 36 (N= 33, 24) | 0.10 ± 0.33 | 1.25 ± 0.40 |
| Week 52 (N= 15, 9) | -0.04 ± 0.46 | 1.00 ± 0.59 |
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.38 ± 0.27 | 0.81 ± 0.25 |
| Week 12 | 0.73 ± 0.36 | 1.36 ± 0.33 |
| Week 24 | 0.78 ± 0.42 | 1.86 ± 0.38 |
| Week 36 | 0.89 ± 0.41 | 2.23 ± 0.38 |
| Week 52 | 0.82 ± 0.41 | 2.35 ± 0.38 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | -0.10 ± 0.45 | 1.24 ± 0.44 |
| Week 12 (N= 73, 68) | -0.18 ± 0.58 | 1.83 ± 0.58 |
| Week 24 (N= 50, 36) | -0.82 ± 0.54 | 0.77 ± 0.60 |
| Week 36 (N= 33, 24) | -1.35 ± 0.57 | 0.93 ± 0.63 |
| Week 52 (N= 15, 9) | -1.62 ± 0.83 | 1.78 ± 1.05 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.05 ± 0.50 | 1.13 ± 0.46 |
| Week 12 | 0.10 ± 0.61 | 2.03 ± 0.56 |
| Week 24 | 0.25 ± 0.66 | 3.08 ± 0.61 |
| Week 36 | 0.60 ± 0.66 | 3.69 ± 0.60 |
| Week 52 | 0.58 ± 0.66 | 4.02 ± 0.60 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.02 ± 0.38 | 0.68 ± 0.36 |
| Week 12 (N= 73, 68) | -0.01 ± 0.45 | 0.80 ± 0.45 |
| Week 24 (N= 50, 36) | -0.71 ± 0.40 | 0.46 ± 0.43 |
| Week 36 (N= 33, 24) | -0.80 ± 0.50 | 0.70 ± 0.56 |
| Week 52 (N= 15, 9) | 1.37 ± 1.39 | 1.06 ± 1.77 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | -0.24 ± 0.40 | 0.61 ± 0.36 |
| Week 12 | -0.15 ± 0.48 | 1.09 ± 0.43 |
| Week 24 | -0.09 ± 0.49 | 1.50 ± 0.44 |
| Week 36 | -0.07 ± 0.52 | 1.56 ± 0.47 |
| Week 52 | 0.34 ± 0.56 | 1.57 ± 0.50 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | -0.18 ± 0.31 | 0.32 ± 0.30 |
| Week 12 (N= 73, 68) | -0.44 ± 0.38 | 0.69 ± 0.39 |
| Week 24 (N= 50, 36) | -1.26 ± 0.34 | 0.27 ± 0.38 |
| Week 36 (N= 33, 24) | -1.31 ± 0.44 | 0.17 ± 0.50 |
| Week 52 (N= 15, 9) | -0.37 ± 0.99 | -0.30 ± 1.24 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | -0.32 ± 0.34 | 0.33 ± 0.31 |
| Week 12 | -0.19 ± 0.41 | 1.19 ± 0.38 |
| Week 24 | -0.29 ± 0.44 | 1.76 ± 0.41 |
| Week 36 | 0.00 ± 0.45 | 1.95 ± 0.42 |
| Week 52 | 0.29 ± 0.48 | 1.97 ± 0.45 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.19 ± 0.19 | 0.55 ± 0.18 |
| Week 12 (N= 73, 68) | 0.33 ± 0.28 | 0.82 ± 0.29 |
| Week 24 (N= 50, 36) | -0.26 ± 0.27 | 0.81 ± 0.31 |
| Week 36 (N= 33, 24) | -0.13 ± 0.29 | 0.94 ± 0.34 |
| Week 52 (N= 15, 9) | -0.20 ± 0.40 | 0.94 ± 0.50 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.32 ± 0.22 | 0.65 ± 0.21 |
| Week 12 | 0.52 ± 0.30 | 0.94 ± 0.28 |
| Week 24 | 0.50 ± 0.36 | 1.31 ± 0.33 |
| Week 36 | 0.57 ± 0.36 | 1.63 ± 0.33 |
| Week 52 | 0.49 ± 0.37 | 1.75 ± 0.34 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 (N= 81, 84) | 0.19 ± 0.25 | 0.66 ± 0.24 |
| Week 12 (N= 73, 68) | 0.54 ± 0.29 | 0.78 ± 0.29 |
| Week 24 (N= 50, 36) | 0.61 ± 0.28 | 0.58 ± 0.32 |
| Week 36 (N= 33, 24) | 0.46 ± 0.33 | 0.71 ± 0.39 |
| Week 52 (N= 15, 9) | 0.04 ± 0.43 | 0.28 ± 0.56 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole | Placebo |
|---|---|---|
| Week 6 | 0.19 ± 0.27 | 0.85 ± 0.25 |
| Week 12 | 0.86 ± 0.32 | 1.41 ± 0.30 |
| Week 24 | 1.07 ± 0.32 | 1.64 ± 0.30 |
| Week 36 | 1.09 ± 0.32 | 1.79 ± 0.30 |
| Week 52 | 1.17 ± 0.31 | 1.88 ± 0.29 |
Collected over Adverse events reported from the signing of the informed consent throughout the stabilization and treatment period followed by a follow-up phone call or clinic visit (study physician's discretion) of 30 (+2) days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Blind Stabilization Phase | — | 34/464 (7.3%) | 148/464 (31.9%) |
| Brexpiprazole (Double-blind Maintenance Phase) | — | 3/97 (3.1%) | 0/97 (0%) |
| Placebo (Double-blnd Maintenance Phase) | — | 11/104 (10.6%) | 0/104 (0%) |
| Event | Single Blind Stabilization Phase | Brexpiprazole (Double-blind Maintenance Phase) | Placebo (Double-blnd Maintenance Phase) |
|---|---|---|---|
| SchizophreniaPsychiatric disorders | 22/464 | 1/97 | 5/104 |
| Psychotic disorderPsychiatric disorders | 0/464 | 1/97 | 4/104 |
| Hepatic enzyme increasedInvestigations | 0/464 | 1/97 | 0/104 |
| Angina unstableCardiac disorders | 0/464 | 0/97 | 1/104 |
| ArrhythmiaCardiac disorders | 0/464 | 0/97 | 1/104 |
| Suicidal ideationPsychiatric disorders | 3/464 | 0/97 | 1/104 |
| HypertensionVascular disorders | 0/464 | 0/97 | 1/104 |
| Psychotic disorderPsychiatric disorders | 3/464 | 0/97 | 0/104 |
| Gun shot woundInjury, poisoning and procedural complications | 1/464 | 0/97 | 0/104 |
| Oedema peripheralGeneral disorders | 1/464 | 0/97 | 0/104 |
| Event | Single Blind Stabilization Phase | Brexpiprazole (Double-blind Maintenance Phase) | Placebo (Double-blnd Maintenance Phase) |
|---|---|---|---|
| InsomniaNervous system disorders | 56/464 | 0/97 | 0/104 |
| AkathisiaNervous system disorders | 42/464 | 0/97 | 0/104 |
| AgitationPsychiatric disorders | 30/464 | 0/97 | 0/104 |
| SchizophreniaNervous system disorders | 28/464 | 0/97 | 0/104 |
| Weight increasedInvestigations | 24/464 | 0/97 | 0/104 |
| HeadacheNervous system disorders | 23/464 | 0/97 | 0/104 |
The enrolled sample was defined as all participants who signed the informed consent for the trial and entered Phase A or Phase B.
| Age, Continuous(years) | Phase C - Brexpiprazole (Double-Blind Maintenance Phase) | Phase C - Placebo (Double-Blind Maintenance Phase) | Total |
|---|---|---|---|
| Mean | 38.8 ± 10.7 | 41.6 ± 10.6 | 40.2 ± 10.7 |
| Gender(Participants) | Phase C - Brexpiprazole (Double-Blind Maintenance Phase) | Phase C - Placebo (Double-Blind Maintenance Phase) | Total |
|---|---|---|---|
| Female | 39 | 40 | 79 |
| Male | 58 | 65 | 123 |
The record gives a start of Oct 2012, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →